Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Astegolimab in COPD
NCT05878769Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 40
01
Overview
A Phase 3 trial of astegolimab in chronic obstructive pulmonary disease (COPD), sponsored by Roche. Started Jun 2023; status: active, not recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05878769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878769.